WS #15143
Eli Lilly reported that its experimental combination regimen EloraTZP cut weight up to 23.3% versus 14.8% for Tirzepatide in a Phase 2b diabetes trial, with plans for Phase 3 in Q4. This data provides a strong bullish signal for the healthcare sector, particularly for obesity and diabetes treatments, demonstrating continued innovation and market leadership in the weight-loss drug space.
Healthcare & Obesity Drugs
Eli Lilly reported that its experimental combination regimen EloraTZP cut weight up to 23.3% versus 14.8% for Tirzepatide in a Phase 2b diabetes trial, with plans for Phase 3 in Q4. This data provides a strong bullish signal for the healthcare sector, particularly for obesity and diabetes treatments, demonstrating continued innovation and market leadership in the weight-loss drug space.